CHARLES TILLEY: Open Payments
NPI 1467502286 · LE MARS, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$750 in 52 payments from 10 companies in 2025. Trend: 2023 $567 · 2024 $594 · 2025 $750
Food & beverage: $638Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $192 |
| Teva Pharmaceuticals USA, Inc. | 6 | $163 |
| Neurocrine BioSciences, Inc. | 6 | $106 |
| Alkermes, Inc. | 4 | $79 |
| Janssen Pharmaceuticals, Inc | 4 | $67 |
| Otsuka America Pharmaceutical, Inc. | 4 | $67 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
Products named: VRAYLAR, INGREZZA, ARISTADA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, UZEDY, COBENFY, Qelbree.
Industry payments across IA — which companies pay providers there.
